Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD.

MLA

Leiding, Jennifer W., et al. “Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not Affect Allogeneic HCT Outcomes for CGD.” Blood, vol. 142, no. 24, Dec. 2023, pp. 2105–18. EBSCOhost, https://doi.org/10.1182/blood.2022019586.

APA

Leiding, J. W., Arnold, D. E., Parikh, S., Logan, B., Marsh, R. A., Griffith, L. M., Wu, R., Kidd, S., Mallhi, K., Chellapandian, D., Si Lim, S. J., Grunebaum, E., Falcone, E. L., Murguia-Favela, L., Grossman, D., Prasad, V. K., Heimall, J. R., Touzot, F., Burroughs, L. M., … Kang, E. M. (2023). Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood, 142(24), 2105–2118. https://doi.org/10.1182/blood.2022019586

Chicago

Leiding, Jennifer W, Danielle E Arnold, Suhag Parikh, Brent Logan, Rebecca A Marsh, Linda M Griffith, Ruizhe Wu, et al. 2023. “Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not Affect Allogeneic HCT Outcomes for CGD.” Blood 142 (24): 2105–18. doi:10.1182/blood.2022019586.